Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

NewsGuard 100/100 Score

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index (a measure of glucose handling by the body) did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS). This double-blind placebo-controlled trial consisted of three arms: placebo, low dose, and high dose EPI-A0001. The improvement in the FARS was statistically significant in both the high and low dose groups in comparison to placebo. There were no differences in the rates of drug-related adverse events between the placebo group and each of the drug-treated groups.

EPI-A0001 has received orphan designation from FDA. On February 25, 2010, the FDA granted Fast Track designation to EPI-A0001 for Friedreich's ataxia.

The results of this study are preliminary. Additional clinical trials will be required to determine the safety and effectiveness of EPI-A0001 for the proposed indication.

SOURCE Edison Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pistachios: Ideal nighttime snack for prediabetic patients to manage blood glucose levels